Mainz Biomed BV

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.

ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023

Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update

Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics

Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom

Israel has one of the highest screening compliance rates in the world with over one million people being screened each year Israel has one of the highest screening compliance rates in the world with over one million people being screened each year

Mainz Biomed Announces Collaboration with Fugene Genetics in Israel

Provides option to access capital to support commercial and clinical programs Provides option to access capital to support commercial and clinical programs

Mainz Biomed Secures up to $50M in New Funding

The Company's innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología The Company's innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología

Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain

ColoAlert® will be offered to an addressable market of 6 million patients through 15 laboratories. BERKELEY, Calif.

Mainz Biomed Expands into Romania Through Partnership with Bioclinica

Total addressable market in Poland is estimated at 21 million patients BERKELEY, Calif. and MAINZ, Germany, May 31, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp.

Mainz Biomed Expands Commercial Footprint into Poland

Employees found the online patient portal, through which they ordered the ColoAlert® test, easy-to-use and convenient

Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper

ColoAlert® Revenue Increases 152% Year Over Year BERKELEY, Calif. and MAINZ, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update

BERKELEY, Calif. and MAINZ, Germany, May 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a research collaboration with Microba Life Sciences (ASX: MAP) (“Microba”), a precision microbiome company leveraging a world-leading technology platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases. As part of the agreement, Microba and Mainz Biomed will conduct a pilot research project utilizing Microba's proprietary metagenomic sequencing technology and bioinformatic tools to potentially discover novel microbiome biomarkers for pancreatic cancer detection.

Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

Eurofins GeLaMed to provide test kit processing of ColoAlert® through Germany BERKELEY, Calif. and MAINZ, Germany, May 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has added Eurofins GeLaMed to its network of lab partners offering PCR test kit processing of ColoAlert®, its flagship product that is a highly efficacious and easy to use at-home screening test for colorectal cancer (CRC).

Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners

Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery

Mainz Biomed to Participate in Digestive Disease Week 2023

BERKELEY, Calif. and MAINZ, Germany, April 27, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activities in May:

Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany

The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients

Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal

ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Provides Full Year 2022 Financial Results

BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies have selected ColoAlert®, the Company's highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate health programs.

Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany

BERKELEY, Calif. and MAINZ, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today results of an independent feasibility study conducted in collaboration with members of the Early Detection Research Network (EDRN) to evaluate the Company's portfolio of five novel gene expression (mRNA) biomarkers acquired from Université de Sherbrooke in January, 2022.

Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas

BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that Bill Caragol, the Company's CFO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 22-23, 2023. The presentation will begin at 12:15 ET on March 22, 2023 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_apzthw9PRlOrUq5PSD5Dcw. Mainz Biomed will also host virtual one-on-ones with investors on Wednesday and Thursday, March 22-23, 2023. To register for the presentation or one-on-ones, visit www.sidoti.com/events. Registration is free and you don't need to be a Sidoti client. About Sidoti & Company For over two decades, Sidoti & Company (http://www.sidoti.com) has been a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $100 million-$5 billion market cap range. The firm's approach affords companies and institutional clients a combination of high-quality research, a small- and microcap-focused nationwide sales effort, broad access to corporate management teams, and extensive trading support. Sidoti serves 500+ institutional clients in North America. About ColoAlert ColoAlert, Mainz Biomed's flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Gies et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs, and via direct sales. To receive marketing approval in the US, ColoAlert will be evaluated in the FDA-registration trial ‘ReconAAsense'. Once approved in the US, the Company's commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.  About Colorectal Cancer Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US.  About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com or follow us on LinkedIn , Twitter and Facebook .   For media inquiries, please contact press@mainzbiomed.com

Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23

Labor Staber to actively market and sell ColoAlert to its physician and patient network. Labor Staber to actively market and sell ColoAlert to its physician and patient network.

Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany

Sponsor of Gastro Update 2023, 2-day scientific and training events for gastroenterology professionals

Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection

Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer.

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023

Virtual Fireside Chat via Paltalk Platform Virtual Fireside Chat via Paltalk Platform

Mainz Biomed to Appear on ClearThink IR's Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET

Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies

Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

Continued roll-out in Europe with onboarding of new lab partners Continued roll-out in Europe with onboarding of new lab partners

Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK

Patient Access Initiative Addresses €1 Billion Annual Market in Germany Patient Access Initiative Addresses €1 Billion Annual Market in Germany

News for Mainz Biomed BV Stock (MYNZ)